1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
678D9EE4B4B959EB4852569670059B43F
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/effective-timing-of-marketing-activities-part-2
18
19
203.95.23.35
21
22
23
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing New Product Development and Launch Managing Development Process Time to Market

Effective Timing of Marketing Activities -- Part 2

Excerpt in Cart

ID: 3613


Features:


Words: 1,273


Published: Pre-2013


Delivery Format: Online


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Parallel process branding & other marketing tasks to move drugs to market quickly with multiple indications. Pharmaceutical manufacturers recognize the importance of balancing speed to market with speed to market penetration. The result of a balanced, successful development process can be a product that has the optimal molecular construction, technical specs, and market demand, with multiple approved indications. The struggle to work with such a balanced, multi-indication product drove one benchmark partner to adopt a strategy of parallel processing tasks at the end of the development process. The company believes that broad labeling is crucial to achieving and maintaining market share, a far more important strategic goal than rapid but short-lived market success. The company maintains a single development team, but members focus on different indications so that there are de facto subteams working on up to 20 different indications at the end of Phase III ...

Industries Profiled:
Pharmaceutical


Companies Profiled:
A Leading Pharmaceutical Company


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.